NCT00431912View on ClinicalTrials.gov

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

September 30, 2011

Conditions
Cutaneous T-cell Lymphoma
Interventions
DRUG

APO866

APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles

Trial Locations (5)

8036

Department of Dermatology, Medical University Graz, Graz

8091

Department of Dermatology, University Hospital of Zürich, Zurich

44093

department of Dermatologie, Hotel Dieu, Nantes

68167

University Clinic for Dermatology, Medical Faculty of Mannheim of the Heidelberg University, Mannheim

94010

Deapartment of Dermatology, Créteil

Sponsors
All Listed Sponsors
lead

Valerio Therapeutics

INDUSTRY